Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Host-directed therapy: A new type of TB treatment

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy. [More]
Study shows caregivers' allergy perceptions are not always accurate

Study shows caregivers' allergy perceptions are not always accurate

It's tough being the parent of a child with food allergies. Constant vigilance is needed for everything your child eats, when a single food item containing a hidden ingredient can be fatal. [More]
EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. [More]
Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth. [More]
New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases. [More]
Definiens closes €15M financing round to expand into digital tissue diagnostics

Definiens closes €15M financing round to expand into digital tissue diagnostics

Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million. [More]
Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. [More]
New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies. [More]
Transfer of few immune cells can protect immunodeficient patients

Transfer of few immune cells can protect immunodeficient patients

The cells of the human immune system are created from special stem cells in the bone marrow. In diseases affecting the bone marrow, such as leukemia, the degenerate cells must be destroyed using radiation or chemotherapy. [More]
Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer Inc. and Cellectis today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. [More]
Tips to help kids enjoy healthy, symptom-free days in classroom and on sports field

Tips to help kids enjoy healthy, symptom-free days in classroom and on sports field

Your kids may be enjoying the lazy days of summer, but if they have asthma, allergies - or both - they need to be prepared for back-to-school. And so do their classrooms. More than 10 million kids under age 18 have asthma, and 11 percent suffer from respiratory allergies. About 6 percent have also been diagnosed with food allergies. [More]
Lipids efficiently kill leukemia cells

Lipids efficiently kill leukemia cells

T cells use a novel mechanism to fight leukemia. They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules. [More]
Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer. [More]
TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France. [More]
Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says. [More]
Knowing summer allergies

Knowing summer allergies

As if a runny nose and red eyes weren't enough to ruin your warm weather look, summer allergies can gift you with even more than you've bargained for this year. In fact, some unusual symptoms can leave you looking like you lost a round in a boxing ring. [More]
Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19. [More]